

Pouneh Simpson Senior Director of Finance CFAOC Presentation December 28, 2023







OUR MISSION Accelerating world class science to deliver transformative regenerative medicine treatments in an equitable manner to a diverse California and world







Prop 14 Overview

2022/23 Budget Financial Results

Major Drivers


2023/24 Approved Budget Overview

Major Drivers

2021/22 Financial Audit








RM Statutory Categories and Expenditure Caps



As of November 2023, Dollars in Millions







FY 2022/23 Financial Results and Discussion





- Completion of the second full year of CIRM relaunch
- Ramp-up
 - Increased staff levels due to increased workload
 - Increase in number of reviews based on ramp-up
 - CIRM moved into new office in South San Francisco and starting a hybrid working environment.
- Resumption of in-person meetings and travel to scientific conferences.





Category	FY 22/23 Budget	FY 22/23 Actual	Variance
Employee Expense	18,421	15,562	-2,859 (-16%)
External Services	2,382	3,164	782 (33%)
Reviews, Meetings and Workshops	1,815	894	-921 (-51%)
Memberships & Training	235	210	-25 (-11%)
Travel	212	158	-54 (-26%)
Office Expenses	1,594	1,125	-469 (-30%)
Rent	1,555	1,625	70 (5%)
Total	26,214	22,738	-3,476 (-13%)

• Numbers are in thousands of dollars (\$000).

• Minor variances due to rounding.





Lower Expense:

- Employee Expenses under budget by \$2,859,000 (-16%) because of delays in hiring, staff turnover, and transit and per diem savings.
- Reviews Meetings and Workshops under budget by \$921,000 (-51%) because of in-person meetings becoming virtual or workshops being postponed.
- Office Expenses under budget by \$469,000 (-30%) because actual move costs were lower than budgeted and some costs were more appropriately displayed as external services.





Higher Expense: External Services

Consultants for New initiatives. For example:

- Business Development IP and Industry Activities
- AAWG Roadmap discussions
- Review- Facilities Working Group
- IT Upgraded IT Security and Infrastructure
- Finance Automation of financial processes
- Estimated Expense over budget by \$782,000 (33%)





FY 2023/24 ICOC Approved Administrative Budget





Category	FY 22/23 Budget	FY 22/23 Actual	FY 23/24 Approved Budget	Variance FY 23/24 Requested vs 22/23 Actual
Employee Expense	18,421	15,562	19,871*	4,309 (22%)
External Services	2,382	3,164	3,913	749 (19%)
Reviews, Meetings and Workshops	1,815	894	2,109**	1,215 (58%)
Memberships & Training	235	210	298	88 (30%)
Travel	212	158	440	282 (64%)
Equipment & Supplies	1,594	1,125	1,202	77 (6%)
Facilities	1,555	1,625	1,105	-520 (-47%)
Total	26,214	22,738	28,938	6,200 (22%)

* Cost of increased mandated benefits, and ICOC Patient Advocate Per Diem, and a request for 6 new FTE.


** Increase in number and cost of reviews, advisory meetings, and in-person meetings.

• Numbers are in thousands of dollars (\$000). Minor variances due to rounding.





- Overview Proposed Increases
 - Employee Expense 6 additional positions for a total of 66 positions.
 - Reviews/Meetings/Workshops Additional in-person meetings.
 - Membership and Training for increased staff and resumption of pre-pandemic activities.
 - Travel increased for staff due to resumption of pre-pandemic activities.









CIRM Access and Affordability Funding Sources

Prop 14 Access and Affordability Research Funds (2%= \$96M): Grant funds to remove barriers to clinical trials and approved therapies for Cell and Gene Therapies. The CIRM Governing Board has allocated up to \$2.5 million for a duration of up to five years to administer a patient support program.

Prop 14 Access and Affordability Staff (1%= \$55M): Funding for CIRM Staff supporting Access and Affordability strategic initiatives, Access and Affordability Working Group, and program operating expenses.

Fund 1031 CIRM Licensing Revenues and Royalties Fund "Patient Support Fund" (current balance \$16.3M): Updates to annual appropriations levels would be made through a Budget Change Proposal to Dept of Finance.











FY 2021/22 Financial Audit



